Modeling and Workflow Recognition for the Anterior Approach in Total Hip Arthroplasty
Launched by PHILIPP FÜRNSTAHL · Aug 7, 2023
Trial Information
Current as of August 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a specific type of hip surgery called total hip arthroplasty (THA), using a technique known as the direct anterior approach (DAA). The goal is to create a detailed guide that breaks down the surgical process into clear steps. This will help improve the way surgeries are performed and understood. Researchers will analyze videos of the surgery to identify and label each part of the procedure systematically.
To participate in this trial, you need to be between 65 and 74 years old and undergoing your first total hip replacement surgery at one of the participating hospitals. You will also need to provide complete medical imaging data, like CT scans and X-rays of your hip and pelvis, and sign a consent form. If you have had previous hip surgery at the same site or have certain hip or pelvis fractures, you may not be eligible. Participants can expect to contribute to important research that could enhance surgical techniques and improve outcomes for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Primary surgery for total hip arthroplasty (THA) at Balgrist University Hospital, Kantonsspital Baden and Kantonsspital Winterthur
- • Complete radiological data (CT and Hip/Pelvis x-ray)
- • Signed consent
- Exclusion Criteria:
- • Missing or incomplete consent
- • Previous surgery of the hip at the site of the THA
- • Fracture of the hip or pelvis at the site of the THA
About Philipp Fürnstahl
Philipp Fürnstahl is a dedicated clinical trial sponsor known for its commitment to advancing medical research and improving patient outcomes. With a focus on innovative therapies and rigorous scientific methodologies, the organization collaborates with healthcare professionals and research institutions to facilitate the efficient design and execution of clinical studies. Philipp Fürnstahl prioritizes ethical standards and regulatory compliance, ensuring that all trials are conducted with the highest level of integrity and transparency. Their mission is to contribute to the development of safe and effective treatments that address unmet medical needs, ultimately enhancing the quality of care for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baden, Aargau, Switzerland
Zurich, , Switzerland
Winterthur, Zurich, Switzerland
Patients applied
Trial Officials
Philipp Fürnstahl, PhD
Principal Investigator
Balgrist University Hospital
Patrick Zingg, MD
Study Chair
Balgrist University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported